Form 4: Werewolf Therapeutics Director Briggs Morrison Acquires Stock Options

Director Briggs Morrison of Werewolf Therapeutics acquired stock options on May 24, 2024, according to a recent SEC Form 4 filing.

Summary

• On May 24, 2024, Briggs Morrison, a director of Werewolf Therapeutics, Inc. (HOWL), acquired stock options.
• The stock option grants the right to buy 17,500 shares of common stock at an exercise price of $4.88.
• The options vest on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders following the grant date, contingent upon continued service as a director.
• Following the transaction, Morrison directly owns 17,500 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices for directors, aligning their interests with the company's success. There are no explicit negative implications.

Future Outlook

The vesting of the options is contingent upon the director's continued service, aligning their interests with the company's performance.

Industry Context

Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially driving long-term value creation.

Key Dates